NEW YORK ( TheStreet) -- According to readers of TheStreet, the company most likely to benefit from the bed-bug epidemic is agricultural seed giant Monsanto ( MON) -- which also happens to be one the biggest names in the business of manufacturing pest control products.

While Monsanto garnered 21.7% of the votes in our poll on which stock is best poised to profit from the bed-bug outbreak, Sealy ( ZZ) came in a close second, receiving 20.4% of the votes cast. Clorox ( CLX) came in third, with 15.3% of the votes.

E.I. du Pont de Nemours ( DD) picked up 14% of the votes, while Procter & Gamble ( PG) received 12.1%. Rollins ( ROL), Ecolab ( ECL) and Bayer AG ( BAYRY) logged 7.6%, 5.1% and 3.8% respectively.

According to brand and communications company Hall & Partners, its WebWord tool -- which the company uses to monitor online "buzz" for clients and brands it's tracking -- shows that "fail" and "resistant" are among the words most strongly associated with searches on "bed bugs and cure." However, no brand is being singled as a failure. Likewise, no search results were showing up for "cure."

Hall & Partners believes these results indicate an important opportunity for many consumer goods companies. "While people are talking a lot about bed bugs lately, no one seems to know what to do with them," Hall & Partners director Brigette Lytle said.

"If a brand started talking about how they are a cure for bed bugs, they can have a stronghold in the market before anyone else gets out there with it."

According to reports, the bed-bug outbreak has reached record levels across the U.S., with Google's ( GOOG) New York City office being among the latest to fall victim to the critters.

-- Written by Andrea Tse in New York.

>To contact the writer of this article, click here: Andrea Tse.

>To follow the writer on Twitter, go to Andrea Tse.

>To submit a news tip, send an email to:


Copyright 2010 Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.